(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
25 of the world’s best sandwiches- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
- Figure out How to Plan for Your Web-based Degree monetarily
- Vote In favor of Your Favored Occasion Arranging Administration
- 37 Things Just Individuals Experiencing childhood during the 80s Will Comprehend
- The 25 Most Notable Style Crossroads in History
- Go on A Careful spending plan: Modest Objections for Your List of must-dos
- 8 Espresso Bean Starting points All over the Planet
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
